OncoSil Medical Executes 532 Options at AUD $0.90, Boosting Total Shares to 30.89 Million

Details on OncoSil Medical’s Option Exercise and Capital Base Expansion

OncoSil Medical Ltd, an ASX-listed biomedical firm, has completed the exercise of 532 options previously classified as OSLOE securities expiring on 30 June 2027. This exercise, conducted on 17 July 2026, converted existing convertible securities into equity shares, aligning with the company’s capital management strategy.

The exercised options were part of an existing class, meaning this transaction converted already-issued convertible securities rather than issuing new capital. The resulting 532 ordinary shares were issued on the same day as the exercise and rank equally with existing shares, maintaining consistent shareholder rights.

Exercise Price and Financial Considerations

The options were exercised at AUD $0.90 per share, with cash consideration received in Australian dollars. While the company did not disclose the total cash amount raised, the implied proceeds from this exercise approximate AUD $478.80. This fixed exercise price was set at the original issuance of the options, allowing holders to acquire shares at a predetermined cost and demonstrating the utilisation of OncoSil Medical’s convertible securities program.

Impact on Total Issued Share Capital

Following the quotation of these shares, OncoSil Medical’s total issued ordinary fully paid shares increased to 30,889,430 on the ASX. Although the addition of 532 shares is modest, it reflects ongoing conversion of options into ordinary equity.

The company continues to hold a substantial portfolio of options, including 12,081,594 OSLOE options expiring 30 June 2027, 2,140,009 OSLOC options expiring 20 December 2027, 7,662,399 OSLOD options expiring 31 July 2027, and 4,253,161 OSLO options expiring 30 April 2027. Additionally, OncoSil Medical has unquoted performance rights and options expiring up to 2030, with exercise prices ranging from nil to AUD $48.00 per share.

Convertible Securities Portfolio and Future Conversion Potential

The company’s quoted options total approximately 26.24 million securities across four series with varying expiry dates, indicating significant near-term conversion potential. The OSLOE series, from which the recent exercise occurred, remains the largest with over 12 million securities outstanding.

Unquoted convertible securities add approximately 1.35 million shares’ worth of potential dilution, including 687,092 nil-exercise-price options (OSLAC) exercisable without cash payment prior to their 30 June 2029 expiry.

Regulatory Compliance and ASX Quotation Process

OncoSil Medical applied for quotation of the 532 ordinary shares in compliance with ASX Listing Rules, specifically Appendix 2A, which governs the listing of securities from option exercises or convertible security conversions. The application was submitted on 17 July 2026, the same day as the exercise, ensuring timely regulatory adherence.

This process ensures transparency and accurate recording of the company’s capital structure, providing investors and the market with clear visibility of equity changes arising from option exercises or other convertible security conversions.

Company Overview and Market Position

OncoSil Medical Ltd operates in the oncology and brachytherapy medical device sectors and is publicly listed on the ASX. The company is subject to continuous disclosure and reporting obligations, supporting transparency around capital management and financial position.

The management of convertible securities through exercises and quotations demonstrates the company’s disciplined capital management approach. Investors should consider the convertible securities portfolio when assessing potential equity dilution and future share count changes.

Investor Implications and Dilution Considerations

The option exercise price of AUD $0.90 indicates optionholders’ valuation threshold for OncoSil Medical shares. While the company did not comment on the rationale behind this exercise, it may reflect confidence in the company’s outlook.

With over 26 million quoted options and 1.35 million unquoted convertible securities outstanding, investors should be aware of potential dilution risks as these instruments may convert to ordinary shares over time. The staggered expiry dates, particularly those clustered in 2027, suggest ongoing conversion activity could impact share ownership and earnings per share.

Upcoming Option Expiry Timeline and Conversion Outlook

Key expiry dates include the OSLAC options (687,092 shares, nil exercise price) expiring 30 June 2029, OSLO options (4.25 million shares) expiring 30 April 2027, OSLOD options (7.66 million shares) expiring 31 July 2027, OSLOC options (2.14 million shares) expiring 20 December 2027, and the largest OSLOE series (12.08 million shares) expiring 30 June 2027.

This expiry schedule suggests concentrated option exercise activity could occur in late 2026 and throughout 2027. Unquoted options expiring as late as November 2030, with exercise prices up to AUD $48.00, indicate longer-term dilution potential tied to future share price performance.

Strategic and Capital Management Insights

The exercise of 532 OSLOE options on 17 July 2026, from a large outstanding class, indicates selective and possibly staged conversion activity. This measured approach may reflect optionholders’ individual strategies or market timing preferences.

For OncoSil Medical, option exercises at fixed strike prices affirm underlying equity value and may signal stakeholder confidence in the company’s operational and commercial progress, although no direct commentary was provided.